Président du Conseil d'administration : M. Pierre Legault
Scrutateurs : Mme. Sophie Bozec et M. Sébastien Bolze
Secrétaire : M. Quentin Durand
Quorum:
40.787 %
4
Agenda
Composition of the Bureau and Quorum
Fiscal Year 2021 Key Highlights
Fiscal Year 2021 Financial Statements
Poxel's New CSR Strategy & Action Plan
Report on Compensations
Reports by Statutory Auditors
Questions & Answers
Vote on the Resolutions
5
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
Original Link
Original Document
Permalink
Disclaimer
Poxel SA published this content on 21 June 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 21 June 2022 14:54:07 UTC.
Poxel is a biopharmaceutical company specializing in developing innovative treatments for metabolic diseases, including non-alcoholic steatohepatitis (NASH) and rare diseases.
TWYMEEG® (Imeglimine), Poxel's lead product and the first in its class of medicines, which targets mitochondrial dysfunction, has been marketed in Japan for the treatment of type 2 diabetes.
For the treatment of NASH, the PXL065 met its primary endpoint in a streamlined Phase II trial, and PXL770 has completed a Phase IIa proof-of-concept study by reaching its objectives. In adrenoleukodystrophy (ALD), a rare inherited metabolic disease, the company intends to initiate Phase IIa proof-of-concept studies with the PXL065 and the PXL770 in patients with adrenomyeloneuropathy (AMN).